Zoetis (ZTS) to Release Earnings on Tuesday

Zoetis (NYSE:ZTS) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect Zoetis to post earnings of $1.41 per share and revenue of $2.20 billion for the quarter. Zoetis has set its FY 2025 guidance at 6.000-6.100 EPS.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Stock Performance

Shares of Zoetis stock opened at $153.78 on Tuesday. The stock has a market cap of $68.61 billion, a price-to-earnings ratio of 28.11, a P/E/G ratio of 2.78 and a beta of 0.92. Zoetis has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company’s fifty day moving average is $158.84 and its 200 day moving average is $168.07.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.30%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ZTS shares. Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Stifel Nicolaus dropped their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Finally, Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $214.40.

Insider Activity

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 in the last three months. 0.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zoetis

A hedge fund recently raised its stake in Zoetis stock. Brighton Jones LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 180.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,629 shares of the company’s stock after buying an additional 2,978 shares during the quarter. Brighton Jones LLC’s holdings in Zoetis were worth $754,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.